rcca-header
A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001
To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex
Protocol Number
Astex SGI-110-06
To Learn More Call
201-510-0910

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Daiichi Sankyo
Protocol Number
AC220-A-U302
To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline
Protocol Number
Stemline Therapeutics STML-401-0314
To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
MolMed
Protocol Number
TK008
To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta
Protocol Number
ACE-CL-006
To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia
Site
East Brunswick, Freehold, Howell, Little Silver
Sponsor
Acerta
Protocol Number
ACE-CL-208
To Learn More Call
201-510-0910

A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy

Sponsor
Helsinn Healthcare SA
Protocol Number
PRAN 16-52
To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse
Sponsor
Astellas
Protocol Number
Astellas 2215-CL-0201
To Learn More Call
201-510-0910

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Type of Cancer
Leukemia
Site
Hackensack
Sponsor
Celgene
Protocol Number
MEDI4736-MDS-001